US Edition
News from MyChesCo
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top MyChesCo News
World Health Organization · United StatesThe head of the UN's health agency on Saturday pushed back against Washington's stated reasons for withdrawing from the World Health Organization, dismissing US criticism of the WHO as "untrue".See the Story
WHO chief says reasons U.S. gave for withdrawing 'untrue'
37% Center coverage: 61 sources
ObesityRoche Holdings AG (OTC:RHHBY) on Tuesday released topline results from the CT388-103 Phase 2 trial of CT-388 for obesity. CT-388 is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity, type 2 diabetes, and other obesity-related comorbidities. Trial Data The 469-patient trial was designed to evaluate the efficacy and safety of CT-388 at low, middle, and high doses. I…See the Story
Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight - Roche Holding (OTC:RHHBY)
60% Center coverage: 5 sources
